| Characteristic | N (%) | Matched therapy (%) | Non-matched therapy (%) | p |
|---|
| N = 711 | N = 596 |
|---|
| Age, years | | | | .38 |
| < 60 | 708 (54.2) | 393 (55.3) | 315 (52.9) | |
| ≥ 60 | 599 (45.8) | 318 (44.7) | 281 (47.1) | |
| Sex | | | | .67 |
| Female | 802 (61.4) | 440 (61.9) | 362 (6.7) | |
| Male | 505 (38.6) | 271 (38.1) | 234 (39.3) | |
| Number of prior therapies | | | | .41 |
| ≤ 3 | 637 (48.7) | 354 (49.8) | 283 (47.5) | |
| > 3 | 670 (51.3) | 357 (5.2) | 313 (52.5) | |
| Performance status | | | | .27 |
| 0–1 | 1211 (92.7) | 664 (93.4) | 547 (91.8) | |
| > 1 | 96 (7.3) | 47 (6.6) | 49 (8.2) | |
| Platelet count, × 109/L | | | | .815 |
| ≤ 440 | 1254 (95.9) | 683 (96.1) | 571 (95.8) | |
| > 440 | 53 (4.1) | 28 (3.9) | 25 (4.2) | |
| Number of metastatic sites | | | | .61 |
| 0-2 | 867 (66.3) | 476 (66.9) | 391 (65.6) | |
| > 2 | 440 (33.7) | 235 (33.1) | 205 (34.4) | |
| Liver metastases | | | | .03 |
| No | 839 (64.2) | 475 (66.8) | 364 (61.1) | |
| Yes | 468 (35.8) | 236 (33.2) | 232 (38.9) | |
| Lactate dehydrogenase, IU/L | | | | < .001 |
| ≤ 618 | 856 (65.5) | 499 (7.2) | 357 (59.9) | |
| > 618 | 451 (34.5) | 212 (29.8) | 239 (4.1) | |
| Albumin, g/dL | | | | .16 |
| < 3.5 | 1185 (9.7) | 652 (91.7) | 533 (89.4) | |
| ≥ 3.5 | 122 (9.3) | 59 (8.3) | 63 (1.6) | |
| Tumor type | | | | N/A* |
| Breast | 177 (13.5) | 120 (16.9) | 57 (9.6) | |
| Colorectal | 238 (18.2) | 90 (12.7) | 148 (24.8) | |
| Endometrial | 55 (4.2) | 40 (5.6) | 15 (2.5) | |
| Gastrointestinal, other | 79 (6.0) | 33 (4.6) | 46 (7.7) | |
| Genitourinary, other | 35 (2.7) | 17 (2.4) | 18 (3.0) | |
| Gynecological, other | 67 (5.1) | 35 (4.9) | 32 (5.4) | |
| Head and neck | 69 (5.3) | 36 (5.1) | 33 (5.5) | |
| Renal | 12 (.9) | 6 (.8) | 6 (.8) | |
| Lung | 114 (8.7) | 71 (1.0) | 43 (7.2) | |
| Melanoma | 155 (11.9) | 101 (14.2) | 54 (9.1) | |
| Other | 55 (4.2) | 33 (4.6) | 22 (3.7) | |
| Ovarian | 132 (1.1) | 59 (8.3) | 73 (12.3) | |
| Pancreatic | 25 (1.9) | 7 (1.0) | 18 (3.0) | |
| Sarcoma | 33 (2.5) | 19 (2.7) | 14 (2.4) | |
| Thyroid | 61 (4.7) | 44 (6.2) | 17 (2.9) | |
- *The distribution of tumor types is imbalanced between the two treatment groups; therefore, the p value is non-applicable
